跳至主要内容
临床试验/NCT04615507
NCT04615507已完成不适用

Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Myopic Population

Johnson & Johnson Vision Care, Inc.12 个研究点 分布在 1 个国家目标入组 71 人开始时间: 2020年10月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
71
试验地点
12
主要终点
Visual Performance LogMAR

研究概览

简要总结

This is a 6-visit, subject-masked, multi-site, 2×3 crossover dispensing trial that will last approximately 2 - 4 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
40 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Potential subjects must satisfy all the following criteria to be enrolled in the study:
  • The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • The subject must be at least 40 years of age and not greater than 70 years of age at the time of consent.
  • Subjects must own a wearable pair of spectacles if required for their distance vision.
  • The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 6 hours per wear day, for 1 month or more duration).
  • The subject must either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or, if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire" (Appendix E).
  • The subject's distance spherical equivalent refraction must be in the range of -1.25 D to -3.75 D in each eye.
  • The subject's refractive cylinder must be ≤0.75 D in each eye.
  • The subject's ADD power must be in the range of +0.75 D to +2.50 D.
  • The subject must have distance best corrected visual acuity of 20/20-3 or better in each eye.

排除标准

  • Potential subjects who meet any of the following criteria will be excluded from participating in the study:
  • Currently pregnant or lactating.
  • Any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
  • Any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
  • Any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, etc.).
  • A history of amblyopia, strabismus or binocular vision abnormality.
  • Use of any of the following medications within 2 weeks prior to enrollment: oral retinoids, oral tetracyclines, anticholinergics, systemic/topical steroids, oral phenothiazines. See section 9.1 for additional details regarding excluded systemic medications.
  • Use of any ocular medication, with the exception of rewetting drops.
  • History of herpetic keratitis.
  • History of irregular cornea.
  • History of pathological dry eye.
  • Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
  • Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
  • Any known hypersensitivity or allergic reaction to non-preserved rewetting drop solutions or sodium fluorescein.
  • Exclusion Criteria after Baseline:
  • Clinically significant (Grade 2 or greater) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.
  • Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions.
  • Any current ocular infection or inflammation.
  • Any current ocular abnormality that may interfere with contact lens wear

结局指标

主要结局

Visual Performance LogMAR

时间窗: 1-Week Follow-up within each wearing period

Binocular visual performance on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters), intermediate (64 centimeters) and near (40 centimeters) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. The room illuminance was required to be between 7.3 and 7.9 EV (394-597 lux). For Distance (4 meters), the acceptable range for the chart luminance was 10.5-10.7 EV (181 208 cd/m2). For Intermediate (64cm) and Near (40cm), the acceptable range for the chart luminance 10.8-11.1 EV (223-274 cd/m2). Letter-by letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.

次要结局

  • Vision Scores(1-Week Follow-up within each wearing period)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验